Protocol Ledger

NCT04949191 · Phase II · TERMINATED

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Interventional Phase II clinical trial protocol NCT04949191 sponsored by Incyte in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-08 Enrollment: 10 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04949191
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)10 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04949191
Protocol FieldVerified Registry Value
NCT IdentifierNCT04949191
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment10 participants (ACTUAL)
Registered Start Date2021-07-08
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04949191
Hospital Research SiteLocationSite Profile
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyOpen Hospital Dossier ->
Kanagawa Cancer CenterYokohama, JapanOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI